Broadly Neutralizing Antibodies and the Development of Vaccines

被引：13
作者：
Haynes, Barton F. [1 ,2 ,3 ]
Bradley, Todd [1 ,3 ]
机构：
[1] Duke Univ, Sch Med, Duke Human Vaccine Inst, Durham, NC 27710 USA
[2] Duke Univ, Sch Med, Dept Med, Durham, NC 27710 USA
[3] Duke Univ, Sch Med, Dept Immunol, Durham, NC 27710 USA
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2015年 / 313卷 / 24期
关键词：
HIV-1; ANTIBODY; IN-VIVO; PROTECTION;
D O I：
10.1001/jama.2015.2427
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2419 / 2420
页数：2
相关论文
共 50 条
  • [41] Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic
    Spencer, David A.
    Shapiro, Mariya B.
    Haigwood, Nancy L.
    Hessell, Ann J.
    FRONTIERS IN PUBLIC HEALTH, 2021, 9
  • [42] Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System
    Bhiman, Jinal N.
    Lynch, Rebecca M.
    CURRENT HIV/AIDS REPORTS, 2017, 14 (02) : 54 - 62
  • [43] Use of broadly neutralizing antibodies in pediatric HIV for treatment and remission
    Shapiro, Roger L.
    Masheto, Gaerolwe
    Ajibola, Gbolahan
    CURRENT OPINION IN HIV AND AIDS, 2025, 20 (03) : 279 - 286
  • [44] HIV therapy by a combination of broadly neutralizing antibodies in humanized mice
    Klein, Florian
    Halper-Stromberg, Ariel
    Horwitz, Joshua A.
    Gruell, Henning
    Scheid, Johannes F.
    Bournazos, Stylianos
    Mouquet, Hugo
    Spatz, Linda A.
    Diskin, Ron
    Abadir, Alexander
    Zang, Trinity
    Dorner, Marcus
    Billerbeck, Eva
    Labitt, Rachael N.
    Gaebler, Christian
    Marcovecchio, Paola M.
    Incesu, Reha-Baris
    Eisenreich, Thomas R.
    Bieniasz, Paul D.
    Seaman, Michael S.
    Bjorkman, Pamela J.
    Ravetch, Jeffrey V.
    Ploss, Alexander
    Nussenzweig, Michel C.
    NATURE, 2012, 492 (7427) : 118 - +
  • [45] Use of broadly neutralizing antibodies for HIV-1 prevention
    Pegu, Amarendra
    Hessell, Ann J.
    Mascola, John R.
    Haigwood, Nancy L.
    IMMUNOLOGICAL REVIEWS, 2017, 275 (01) : 296 - 312
  • [46] Broadly Neutralizing Antibodies for Influenza: Passive Immunotherapy and Intranasal Vaccination
    Biswas, Mrityunjoy
    Yamazaki, Tatsuya
    Chiba, Joe
    Akashi-Takamura, Sachiko
    VACCINES, 2020, 8 (03) : 1 - 15
  • [47] HIV Broadly Neutralizing Antibodies: VRC01 and Beyond
    Wu, Xueling
    HIV VACCINES AND CURE: THE PATH TOWARDS FINDING AN EFFECTIVE CURE AND VACCINE, 2018, 1075 : 53 - 72
  • [48] Neutralizing the threat: harnessing broadly neutralizing antibodies against HIV-1 for treatment and prevention
    Becerra, Juan C.
    Hitchcock, Lauren
    Vu, Khoa
    Gach, Johannes S.
    MICROBIAL CELL, 2024, 11 (01): : 207 - 220
  • [49] HIV-1 Envelope gp41 Broadly Neutralizing Antibodies: Hurdles for Vaccine Development
    Verkoczy, Laurent
    Kelsoe, Garnett
    Haynes, Barton F.
    PLOS PATHOGENS, 2014, 10 (05)
  • [50] HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies
    Richardson, Simone I.
    Chung, Amy W.
    Natarajan, Harini
    Mabvakure, Batsirai
    Mkhize, Nonhlanhla N.
    Garrett, Nigel
    Karim, Salim Abdool
    Moore, Penny L.
    Ackerman, Margaret E.
    Alter, Galit
    Morris, Lynn
    PLOS PATHOGENS, 2018, 14 (04)
12345